📊 ALMS Key Takeaways
Is Alumis Inc.. (ALMS) a Good Investment?
Alumis is a pre-revenue pharmaceutical company with severe cash burn and unsustainable operating losses. Despite holding adequate cash reserves ($65.3M), the company is burning approximately $298M annually in free cash flow, indicating a runway of less than 3 quarters at current burn rates. Without demonstrated revenue generation or clear path to profitability, the fundamental financial position is critically deteriorating.
Alumis shows extremely weak current fundamentals, with minimal revenue relative to its cost base, deeply negative operating and net margins, and nearly $300M of annual free cash outflow. The balance sheet is a mitigating factor because liquidity is strong and leverage is negligible, but the business still depends on translating pipeline spending into durable revenue before cash burn materially erodes that cushion.
Why Buy Alumis Inc.. Stock? ALMS Key Strengths
- Strong liquidity position with $65.3M cash and 6.01x current ratio providing near-term operational flexibility
- Low leverage with minimal debt obligations reducing immediate refinancing risk
- Substantial asset base of $488M suggests intellectual property or development assets in pharmaceutical pipeline
- Strong liquidity with a 6.01x current ratio and meaningful cash relative to liabilities
- No meaningful balance-sheet leverage, reducing refinancing and solvency pressure
- Positive reported revenue indicates at least some non-zero commercial or collaboration inflow
ALMS Stock Risks: Alumis Inc.. Investment Risks
- Catastrophic cash burn of -$298.3M in free cash flow annually will deplete reserves within 2-3 quarters at current rates
- Minimal revenue of $22.1M against -$357.4M operating loss indicates no viable commercial operations or product market fit
- Negative net margin of -679.9% and -$150.4M net loss demonstrate inability to control costs relative to revenue
- Early-stage pharma company with unproven drug development success - typical attrition rates are extremely high
- Operating losses and negative cash flow unsustainable without major capital raise, partnership, or acquisition
- Operating model is highly unprofitable, with operating margin of -1615.5% and net margin of -679.9%
- Cash burn is severe, with operating cash flow of -$297.62M and free cash flow of -$298.27M
- Growth quality is weak because revenue remains far too small to support the current expense base
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway - critical for survival timeline
- Revenue growth trajectory - any meaningful revenue would require successful clinical trials and FDA approvals
- Operating expense reduction initiatives and burn rate improvement
- Financing activities and capital raise announcements - likely necessity given cash depletion timeline
- Pipeline clinical trial progress and regulatory milestones for lead candidates
- Quarterly operating cash burn versus cash and equivalents
- Revenue scale-up and operating expense discipline
Alumis Inc.. (ALMS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.01x current ratio provides a solid financial cushion.
ALMS Profit Margin, ROE & Profitability Analysis
ALMS vs Healthcare Sector: How Alumis Inc.. Compares
How Alumis Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alumis Inc.. Stock Overvalued? ALMS Valuation Analysis 2026
Based on fundamental analysis, Alumis Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alumis Inc.. Balance Sheet: ALMS Debt, Cash & Liquidity
ALMS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alumis Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-10.38 indicates the company is currently unprofitable.
ALMS Revenue Growth, EPS Growth & YoY Performance
ALMS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1M | -$49.8M | $-1.06 |
| Q2 2025 | $2.7M | -$39.6M | $-0.61 |
| Q1 2025 | $17.4M | -$49.8M | $-1.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alumis Inc.. Dividends, Buybacks & Capital Allocation
ALMS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alumis Inc.. (CIK: 0001847367)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALMS
What is the AI rating for ALMS?
Alumis Inc.. (ALMS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALMS's key strengths?
Claude: Strong liquidity position with $65.3M cash and 6.01x current ratio providing near-term operational flexibility. Low leverage with minimal debt obligations reducing immediate refinancing risk. ChatGPT: Strong liquidity with a 6.01x current ratio and meaningful cash relative to liabilities. No meaningful balance-sheet leverage, reducing refinancing and solvency pressure.
What are the risks of investing in ALMS?
Claude: Catastrophic cash burn of -$298.3M in free cash flow annually will deplete reserves within 2-3 quarters at current rates. Minimal revenue of $22.1M against -$357.4M operating loss indicates no viable commercial operations or product market fit. ChatGPT: Operating model is highly unprofitable, with operating margin of -1615.5% and net margin of -679.9%. Cash burn is severe, with operating cash flow of -$297.62M and free cash flow of -$298.27M.
What is ALMS's revenue and growth?
Alumis Inc.. reported revenue of $22.1M.
Does ALMS pay dividends?
Alumis Inc.. does not currently pay dividends.
Where can I find ALMS SEC filings?
Official SEC filings for Alumis Inc.. (CIK: 0001847367) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALMS's EPS?
Alumis Inc.. has a diluted EPS of $-1.92.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALMS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alumis Inc.. has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALMS stock overvalued or undervalued?
Valuation metrics for ALMS: ROE of -39.1% (sector avg: 15%), net margin of -679.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALMS stock in 2026?
Our dual AI analysis gives Alumis Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALMS's free cash flow?
Alumis Inc..'s operating cash flow is $-297.6M, with capital expenditures of $653.0K. FCF margin is -1,348.4%.
How does ALMS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -679.9% (avg: 12%), ROE -39.1% (avg: 15%), current ratio 6.01 (avg: 2).